Back to News
Market Impact: 0.2
Sun Pharma's UNLOXCYT Added As NCCN Category 2A Option For Locally Advanced Skin Cancer
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Sun Pharmaceutical said UNLOXCYT (cosibelimab-ipdl) was added as a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma. The article excerpt provides no sales, financial, or market-reaction figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- The U.S. market has never been more focused on one single bet—but AI’s payoff will likely take decades
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide
- CoreWeave’s market confidence erodes as bond yields spike and stock sinks
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Why is Tesla stock falling after-hours today?
- Judge orders Meta to pay $25bn in fines for Facebook privacy violations